Everolimus (RAD001)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Transplantation

Conditions

Cardiac Transplantation

Trial Timeline

Sep 1, 2004 → —

NCT ID

NCT00170794

About Everolimus (RAD001)

Everolimus (RAD001) is a phase 3 stage product being developed by Novartis for Cardiac Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00170794. Target conditions include Cardiac Transplantation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01514448	Approved	Completed	May 21, 2012	Apr 1, 2016	Metastatic Renal Cell Carcinoma (mRCC)
NCT01365468	Phase 2	Terminated	Apr 1, 2012	Apr 1, 2015	Plexiform Neurofibroma Associated With Neurofibromatosis Type 1
NCT01595009	Approved	Completed	Apr 27, 2011	Aug 9, 2016	Neuroendocrine Tumors
NCT01152801	Phase 1	Completed	May 1, 2010	Dec 1, 2013	Metastatic Renal Cell Carcinoma
NCT01022996	Phase 2	Completed	Dec 1, 2009	Nov 1, 2014	Hodgkin Lymphoma
NCT00792766	Phase 1/2	Completed	Dec 1, 2008	Sep 1, 2013	Tuberous Sclerosis
NCT00426530	Phase 1	Completed	Feb 1, 2007	Jun 1, 2010	Breast Neoplasms
NCT00419159	Phase 2	Completed	Dec 1, 2006	Mar 1, 2009	Colorectal Cancer
NCT00154297	Approved	Completed	Jun 1, 2005	—	Renal Transplantation
NCT00170794	Phase 3	Completed	Sep 1, 2004	—	Cardiac Transplantation
NCT00531440	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation
NCT00531063	Phase 3	Completed	Nov 1, 2001	—	Renal Transplantation

Competing Products

20 competing products in Cardiac Transplantation

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	77
regadenoson	Astellas Pharma	Pre-clinical	23
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	52
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	32
Sotagliflozin + Placebo	Sanofi	Phase 2	51

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved